We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Biomarker Test Could Confirm Long COVID Diagnosis

By LabMedica International staff writers
Posted on 12 Aug 2025

Long COVID remains a diagnostic challenge, with clinicians currently relying on a collection of symptoms that appear 12 weeks or more after SARS-CoV-2 infection. More...

No blood tests or biomarkers currently exist to confirm the condition, leaving diagnosis largely presumptive. Now, a new study has uncovered a possible biological signal that could serve as the first specific, quantifiable indicator for the condition.

Researchers from the Translational Genomics Research Institute (TGen, Phoenix, AZ, USA;) have identified SARS-CoV-2 protein fragments within extracellular vesicles (EVs) in the blood of long COVID patients. EVs are tiny, naturally occurring packages that transport proteins, metabolites, and other materials between cells.

The study, reported in Infection, analyzed 56 blood samples from 14 patients over 12 weeks of aerobic exercise training in a long COVID clinical trial. Researchers found 65 distinct protein fragments from the virus’s Pp1ab protein, an RNA replicase enzyme essential for viral replication. This protein is unique to SARS-CoV-2 and not found in uninfected human cells.

Significantly, these viral peptides were demonstrated in each long COVID patient, though not in every sample taken, and were not detected in a separate control group of pre-pandemic EV samples. Their presence supports growing evidence that SARS-CoV-2 may persist in certain tissues long after acute infection. Some scientists suggest lingering viral reservoirs could contribute to the ongoing symptoms of long COVID.

The findings raise key questions about the nature of these peptides—whether they indicate ongoing viral replication or are merely residual “molecular trash” left after viral protein formation. The team has yet to test individuals without long COVID symptoms who have been infected with SARS-CoV-2, leaving the broader significance of the biomarker to be determined.

"This raises the question: is this just continuing to take out the trash from the COVID-infected cell or is this really ongoing replication someplace? I think that’s the mechanistic issue that needs to be resolved in future studies," said William Stringer, M.D., Lundquist Institute investigator and senior author of the study.

Related Links:
TGen


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.